-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On April 26, 2022, Sinopharm Group China Biotechnology and SINOVAC Kexing developed the new coronavirus inactivated vaccine based on the Omicron variant strain (Omicron), respectively, and obtained clinical approval from the State Drug Administration on the same day
.
.
On the 26th, the official public account of China Biotechnology Co.
, Ltd.
"China Bio" announced that on April 26, 2022, Sinopharm Group's Sinopharm Group China Biotech Omicron variant new coronavirus inactivated vaccine received clinical approval from the State Food and Drug Administration
.
On the same day, the reporter learned from Kexing Holding Biotechnology Co.
, Ltd.
that the new coronavirus inactivated vaccine developed by SINOVAC based on the Omicron variant has also been approved for clinical research in China to evaluate the use of the new coronavirus variant vaccine in various types of vaccines.
Safety and immunogenicity in the population
.
, Ltd.
"China Bio" announced that on April 26, 2022, Sinopharm Group's Sinopharm Group China Biotech Omicron variant new coronavirus inactivated vaccine received clinical approval from the State Food and Drug Administration
.
On the same day, the reporter learned from Kexing Holding Biotechnology Co.
, Ltd.
that the new coronavirus inactivated vaccine developed by SINOVAC based on the Omicron variant has also been approved for clinical research in China to evaluate the use of the new coronavirus variant vaccine in various types of vaccines.
Safety and immunogenicity in the population
.
The research and development progress of the two vaccine companies for the new coronavirus inactivated vaccine based on the Omicron variant is almost the same
.
.
In November 2021, Omicron began to spread globally
.
On December 9, 2021, Sinopharm Group China Biotechnology and SINOVAC Kexing introduced the mutant strain of Omicron from the University of Hong Kong on the same day, and started the research and development of the inactivated vaccine of Omicron
.
.
On December 9, 2021, Sinopharm Group China Biotechnology and SINOVAC Kexing introduced the mutant strain of Omicron from the University of Hong Kong on the same day, and started the research and development of the inactivated vaccine of Omicron
.
On April 1, 2022, Sinopharm Group China Biotechnology submitted the clinical application materials for the new coronavirus inactivated vaccine developed based on the Omicron variant to the Hong Kong Department of Health, and obtained the ethics approval on April 12, and obtained clinical research on April 13.
Approval, becoming the world's first inactivated vaccine approved for clinical use
.
The next day, on April 14, SINOVAC’s inactivated new coronavirus vaccine based on the Omicron variant also obtained clinical approval in Hong Kong SAR
.
Approval, becoming the world's first inactivated vaccine approved for clinical use
.
The next day, on April 14, SINOVAC’s inactivated new coronavirus vaccine based on the Omicron variant also obtained clinical approval in Hong Kong SAR
.
At the same time, Sinopharm Group China Biotechnology will submit domestic clinical application materials to the Drug Evaluation Center of the State Food and Drug Administration on a rolling basis from January 26, 2022, and start the technical review; from January 30, SINOVAC Kexing also began to submit to the national The Center for Drug Evaluation of the Food and Drug Administration submits the pre-review materials for clinical trials on a rolling basis
.
On April 26, Sinopharm China Biotech and SINOVAC Kexing's respective inactivated vaccines against the new coronavirus with Omicron variant strains obtained clinical approvals issued by the State Food and Drug Administration of China on the same day
.
.
On April 26, Sinopharm China Biotech and SINOVAC Kexing's respective inactivated vaccines against the new coronavirus with Omicron variant strains obtained clinical approvals issued by the State Food and Drug Administration of China on the same day
.
In the next step, Sinopharm Group China Biotechnology will use the form of a randomized, double-blind, cohort study to conduct a sequential immunization clinical study in people aged 18 and over who have completed 2 or 3 doses of the new crown vaccine to evaluate the Omicron variant.
Safety and immunogenicity of inactivated COVID-19 vaccines
.
SINOVAC also stated that it will actively promote various studies on the new coronavirus variant strains inoculated with prototype vaccines in different populations, as well as the sequential vaccination research on the new coronavirus vaccine prepared from the mutant strains, and continue to make contributions to the prevention and control of the new crown pneumonia epidemic in China and the world.
Actively contribute
.
Safety and immunogenicity of inactivated COVID-19 vaccines
.
SINOVAC also stated that it will actively promote various studies on the new coronavirus variant strains inoculated with prototype vaccines in different populations, as well as the sequential vaccination research on the new coronavirus vaccine prepared from the mutant strains, and continue to make contributions to the prevention and control of the new crown pneumonia epidemic in China and the world.
Actively contribute
.
On April 26, 2022, Sinopharm Group China Biotechnology and SINOVAC Kexing developed the new coronavirus inactivated vaccine based on the Omicron variant strain (Omicron), respectively, and obtained clinical approval from the State Drug Administration on the same day
.
.
On the 26th, the official public account of China Biotechnology Co.
, Ltd.
"China Bio" announced that on April 26, 2022, Sinopharm Group's Sinopharm Group China Biotech Omicron variant new coronavirus inactivated vaccine received clinical approval from the State Food and Drug Administration
.
On the same day, the reporter learned from Kexing Holding Biotechnology Co.
, Ltd.
that the new coronavirus inactivated vaccine developed by SINOVAC based on the Omicron variant has also been approved for clinical research in China to evaluate the use of the new coronavirus variant vaccine in various types of vaccines.
Safety and immunogenicity in the population
.
, Ltd.
"China Bio" announced that on April 26, 2022, Sinopharm Group's Sinopharm Group China Biotech Omicron variant new coronavirus inactivated vaccine received clinical approval from the State Food and Drug Administration
.
On the same day, the reporter learned from Kexing Holding Biotechnology Co.
, Ltd.
that the new coronavirus inactivated vaccine developed by SINOVAC based on the Omicron variant has also been approved for clinical research in China to evaluate the use of the new coronavirus variant vaccine in various types of vaccines.
Safety and immunogenicity in the population
.
The research and development progress of the two vaccine companies for the new coronavirus inactivated vaccine based on the Omicron variant is almost the same
.
.
In November 2021, Omicron began to spread globally
.
On December 9, 2021, Sinopharm Group China Biotechnology and SINOVAC Kexing introduced the mutant strain of Omicron from the University of Hong Kong on the same day, and started the research and development of the inactivated vaccine of Omicron
.
.
On December 9, 2021, Sinopharm Group China Biotechnology and SINOVAC Kexing introduced the mutant strain of Omicron from the University of Hong Kong on the same day, and started the research and development of the inactivated vaccine of Omicron
.
On April 1, 2022, Sinopharm Group China Biotechnology submitted the clinical application materials for the new coronavirus inactivated vaccine developed based on the Omicron variant to the Hong Kong Department of Health, and obtained the ethics approval on April 12, and obtained clinical research on April 13.
Approval, becoming the world's first inactivated vaccine approved for clinical use
.
The next day, on April 14, SINOVAC’s inactivated new coronavirus vaccine based on the Omicron variant also obtained clinical approval in Hong Kong SAR
.
Approval, becoming the world's first inactivated vaccine approved for clinical use
.
The next day, on April 14, SINOVAC’s inactivated new coronavirus vaccine based on the Omicron variant also obtained clinical approval in Hong Kong SAR
.
At the same time, Sinopharm Group China Biotechnology will submit domestic clinical application materials to the Drug Evaluation Center of the State Food and Drug Administration on a rolling basis from January 26, 2022, and start the technical review; from January 30, SINOVAC Kexing also began to submit to the national The Center for Drug Evaluation of the Food and Drug Administration submits the pre-review materials for clinical trials on a rolling basis
.
On April 26, Sinopharm China Biotech and SINOVAC Kexing's respective inactivated vaccines against the new coronavirus with Omicron variant strains obtained clinical approvals issued by the State Food and Drug Administration of China on the same day
.
.
On April 26, Sinopharm China Biotech and SINOVAC Kexing's respective inactivated vaccines against the new coronavirus with Omicron variant strains obtained clinical approvals issued by the State Food and Drug Administration of China on the same day
.
In the next step, Sinopharm Group China Biotechnology will use the form of a randomized, double-blind, cohort study to conduct a sequential immunization clinical study in people aged 18 and over who have completed 2 or 3 doses of the new crown vaccine to evaluate the Omicron variant.
Safety and immunogenicity of inactivated COVID-19 vaccines
.
SINOVAC also stated that it will actively promote various studies on the new coronavirus variant strains inoculated with prototype vaccines in different populations, as well as the sequential vaccination research on the new coronavirus vaccine prepared from the mutant strains, and continue to make contributions to the prevention and control of the new crown pneumonia epidemic in China and the world.
Actively contribute
.
Safety and immunogenicity of inactivated COVID-19 vaccines
.
SINOVAC also stated that it will actively promote various studies on the new coronavirus variant strains inoculated with prototype vaccines in different populations, as well as the sequential vaccination research on the new coronavirus vaccine prepared from the mutant strains, and continue to make contributions to the prevention and control of the new crown pneumonia epidemic in China and the world.
Actively contribute
.
On April 26, 2022, Sinopharm Group China Biotechnology and SINOVAC Kexing developed the new coronavirus inactivated vaccine based on the Omicron variant strain (Omicron), respectively, and obtained clinical approval from the State Drug Administration on the same day
.
.
On the 26th, the official public account of China Biotechnology Co.
, Ltd.
"China Bio" announced that on April 26, 2022, Sinopharm Group's Sinopharm Group China Biotech Omicron variant new coronavirus inactivated vaccine received clinical approval from the State Food and Drug Administration
.
On the same day, the reporter learned from Kexing Holding Biotechnology Co.
, Ltd.
that the new coronavirus inactivated vaccine developed by SINOVAC based on the Omicron variant has also been approved for clinical research in China to evaluate the use of the new coronavirus variant vaccine in various types of vaccines.
Safety and immunogenicity in the population
.
, Ltd.
"China Bio" announced that on April 26, 2022, Sinopharm Group's Sinopharm Group China Biotech Omicron variant new coronavirus inactivated vaccine received clinical approval from the State Food and Drug Administration
.
On the same day, the reporter learned from Kexing Holding Biotechnology Co.
, Ltd.
that the new coronavirus inactivated vaccine developed by SINOVAC based on the Omicron variant has also been approved for clinical research in China to evaluate the use of the new coronavirus variant vaccine in various types of vaccines.
Safety and immunogenicity in the population
.
The research and development progress of the two vaccine companies for the new coronavirus inactivated vaccine based on the Omicron variant is almost the same
.
enterprise enterprise enterprise.
In November 2021, Omicron began to spread globally
.
On December 9, 2021, Sinopharm Group China Biotechnology and SINOVAC Kexing introduced the mutant strain of Omicron from the University of Hong Kong on the same day, and started the research and development of the inactivated vaccine of Omicron
.
.
On December 9, 2021, Sinopharm Group China Biotechnology and SINOVAC Kexing introduced the mutant strain of Omicron from the University of Hong Kong on the same day, and started the research and development of the inactivated vaccine of Omicron
.
On April 1, 2022, Sinopharm Group China Biotechnology submitted the clinical application materials for the new coronavirus inactivated vaccine developed based on the Omicron variant to the Hong Kong Department of Health, and obtained the ethics approval on April 12, and obtained clinical research on April 13.
Approval, becoming the world's first inactivated vaccine approved for clinical use
.
The next day, on April 14, SINOVAC’s inactivated new coronavirus vaccine based on the Omicron variant also obtained clinical approval in Hong Kong SAR
.
Approval, becoming the world's first inactivated vaccine approved for clinical use
.
The next day, on April 14, SINOVAC’s inactivated new coronavirus vaccine based on the Omicron variant also obtained clinical approval in Hong Kong SAR
.
At the same time, Sinopharm Group China Biotechnology will submit domestic clinical application materials to the Drug Evaluation Center of the State Food and Drug Administration on a rolling basis from January 26, 2022, and start the technical review; from January 30, SINOVAC Kexing also began to submit to the national The Center for Drug Evaluation of the Food and Drug Administration submits the pre-review materials for clinical trials on a rolling basis
.
On April 26, Sinopharm China Biotech and SINOVAC Kexing's respective inactivated vaccines against the new coronavirus with Omicron variant strains obtained clinical approvals issued by the State Food and Drug Administration of China on the same day
.
medicines medicines medicines.
On April 26, Sinopharm China Biotech and SINOVAC Kexing's respective inactivated vaccines against the new coronavirus with Omicron variant strains obtained clinical approvals issued by the State Food and Drug Administration of China on the same day
.
In the next step, Sinopharm Group China Biotechnology will use the form of a randomized, double-blind, cohort study to conduct a sequential immunization clinical study in people aged 18 and over who have completed 2 or 3 doses of the new crown vaccine to evaluate the Omicron variant.
Safety and immunogenicity of inactivated COVID-19 vaccines
.
SINOVAC also stated that it will actively promote various studies on the new coronavirus variant strains inoculated with prototype vaccines in different populations, as well as the sequential vaccination research on the new coronavirus vaccine prepared from the mutant strains, and continue to make contributions to the prevention and control of the new crown pneumonia epidemic in China and the world.
Actively contribute
.
Safety and immunogenicity of inactivated COVID-19 vaccines
.
SINOVAC also stated that it will actively promote various studies on the new coronavirus variant strains inoculated with prototype vaccines in different populations, as well as the sequential vaccination research on the new coronavirus vaccine prepared from the mutant strains, and continue to make contributions to the prevention and control of the new crown pneumonia epidemic in China and the world.
Actively contribute
.
